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Background: Efficacy of telmisartan in treating hypertension (HT) in cats has not been largely
investigated.
Objective: Telmisartan oral solution effectively controls systolic arterial blood pressure (SABP)
in hypertensive cats.
Animals: Two-hundred eighty-five client-owned cats with systemic HT.
Methods: Prospective, multicenter, placebo-controlled, randomized, double-blinded study.
Hypertensive cats diagnosed with SABP ≥160 mmHg and ≤200 mmHg without target-organ-
damage were randomized (2 : 1 ratio) to receive 2 mg/kg telmisartan or placebo q24 PO.
A 28-day efficacy phase was followed by a 120-day extended use phase. Efficacy was defined
as significant difference in mean SABP reduction between telmisartan and placebo on Day
14 and group mean reduction in SABP of > 20 mmHg by telmisartan on Day 28 compared to
baseline.
Results: Two-hundred fifty-two cats completed the efficacy and 144 cats the extended use
phases. Mean SABP reduction at Day 14 differed significantly between groups (P < .001). Telmi-
sartan reduced baseline SABP of 179 mmHg by 19.2 (95% confidence interval [CI]:
15.92-22.52) and 24.6 (95% CI: 21.11-28.14) mmHg at Days 14 and 28. The placebo group
baseline SABP of 177 mmHg was reduced by 9.0 (95% CI: 5.30-12.80) and 11.4 (95% CI:
7.94-14.95) mmHg, respectively. Of note, 52% of telmisartan-treated cats had SABP
<150 mmHg at Day 28. Mean SABP reduction by telmisartan in severe (≥180 mmHg) and mod-
erate HT (160-179 mmHg) was comparable and persistent over time.
Conclusions and Clinical Importance: Telmisartan solution (PO) was effective in reducing SABP
in hypertensive cats with SABP ≥160 mmHg and ≤200 mmHg.
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1 | INTRODUCTION
Blood pressure increases with age in cats and systemic hypertension
(HT) and the associated target organ damage (TOD) are commonly
recognized in elderly cats.1,2 Ocular lesions occur in more than 40% of
hypertensive cats.3 Additionally, systemic HT can cause damage to
the brain, kidneys, and heart.4 Consequently, early recognition and
management of systemic HT are crucial. The most common disease
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causing secondary systemic HT in cats is chronic kidney disease
(CKD), followed by hyperthyroidism.4,5 In about 20% of cats with sys-
temic HT, however, no underlying disease is identified and thus are
classified as idiopathic.5 The pathophysiology of systemic HT in cats is
poorly understood. The renin angiotensin aldosterone system (RAAS)
could play a role based on studies in small cohorts of cats with CKD
and idiopathic HT and in cats with hyperthyroidism.6,7 Chronic kidney
disease-related systemic HT is believed to be induced by the activa-
tion of the RAAS.7,8 Angiotensin-II is a central mediator of renal injury
because of its ability to produce glomerular HT resulting in glomerular
damage and activation of pro-inflammatory and profibrotic path-
ways.9,10 Chronic RAAS activation leads to persistent systemic HT via
systemic vasoconstriction, intravascular fluid expansion, and sympa-
thetic activation, mediated by the angiotensin-II type 1 receptor (AT1
receptor).11 The direct inhibition of AT1 receptors with angiotensin
receptor blockers (ARBs) inhibits the activation of these receptors by
multiple mediators, some of which are formed by pathways that do
not involve conventional angiotensin converting enzymes (ACEs) and
leave the angiotensin-II type 2 receptor (AT2 receptors) available for
activation.12 Angiotensin-II type 2 receptors mediate beneficial
actions of angiotensin-II (AT-II) such as vasodilation and natriuresis.13
The underlying mechanisms of systemic HT secondary to hyperthy-
roidism in cats remain to be determined, although dysfunction of the
RAAS is suspected.7 Although the RAAS is implicated in cats with sys-
temic HT of various cause, some cats do appear to have low renin
HT. In human medicine, inhibition of the RAAS appears to benefit
patients with low renin HT.14
Drugs that are used to treat systemic HT in cats include calcium
channel blockers, angiotensin converting enzyme inhibitors (ACEi),
beta-blockers, and diuretics.8,15,16 However, so far, only the calcium
channel blocker amlodipine lowers adequately systemic blood
pressure,3,17,18 which is accompanied by activation of the RAAS sys-
tem.6 Telmisartan is an AT-II receptor antagonist which selectively
binds to the AT1 receptor and thus inhibits the pro-hypertensive
effects of AT-II including vasoconstriction, sodium chloride retention,
vascular and cardiac muscle hypertrophy, and pro-fibrotic effects in
the kidney and cardiovascular systems.19 In human medicine, telmisar-
tan is authorized for the control of systemic HT and cardiovascular
prevention.19–21 In experimental models, telmisartan effectively
inhibits angiotensin-induced pressure responses of cats at doses of
1-3 mg/kg.22
In cats with CKD, telmisartan at the dose of 1 mg/kg PO q24h
proved to be an effective antiproteinuric drug, significantly reducing
proteinuria relative to baseline at all assessment points.23 The goal of
the present field study was to evaluate the efficacy and safety of
telmisartan at reducing systemic HT in cats.
2 | MATERIALS AND METHODS
2.1 | Animals
Client-owned, adult, cats presented during routine clinical practice at
the participating 51 centers from Germany, France, United Kingdom,
Netherlands, and Switzerland were screened for systemic HT. Cats of
either sex were eligible for inclusion if owner informed consent was
given and the cats complied with all inclusion and exclusion criteria.
Diagnosis of systemic HT was based on a systolic blood pres-
sure ≥160 mmHg by Doppler methodology (Parks Non Directional
Ultrasonic Doppler Device Type 811B) on 2 separate screening visits
according to ACVIM guidelines.4 Only trained operators predefined at
each institution made blood pressure measurements. Baseline systolic
arterial blood pressure (SABP) was defined as the mean of the SABP
measurements at the 2 screening visits where SABP at each visit was
calculated as the arithmetic mean of 3 measurements for each animal.
Eligible cats were categorized according to the concurrent dis-
eases that might cause systemic HT using the following criteria. Diag-
nosis of CKD was in accordance with the International Renal Interest
Society (IRIS) guidelines24 based on urine specific gravity <1.035 in
combination with evidence of CKD, that is, present or documented
serum creatinine ≥1.6 mg/dL or irregular, small kidneys on palpation,
abnormal findings during ultrasound or radiographic examination.
Hyperthyroidism was based on history of clinical signs of hyperthy-
roidism with increased thyroxine (total T4) concentration above the
laboratory reference interval. Hyperthyroidism had to be successfully
controlled for >4 weeks as confirmed by a T4 concentration
≤60 nmol/L at screening visits 14 or 2 days before study
inclusion. Cats fulfilling both, criteria for systemic HT with CKD and
hyperthyroidism, were classified as having both diseases. Cats were
classified as idiopathic HT if systemic HT was not associated with
CKD or hyperthyroidism (controlled or uncontrolled).4
Cats were ineligible for inclusion if they had received medications
known to affect blood pressure, such as ACEi, ARBs, calcium channel
blockers, or diuretics <14 days before start of treatment.
Cats were excluded if SABP was >200 mmHg at both screening
visits, SAPB measurements were highly variable in the individual cat
with differences of >20% on 3 consecutive blood pressure measure-
ments at 1 visit, or they had acute or severe TOD, total T4 concentra-
tion > 60 nmol/L, were pregnant, or were lactating. Acute or severe
TOD was defined by the presence of retinopathy/choroidopathy
(acute blindness, retinal detachment, or retinal/vitreal hemorrhage),
signs of hypertensive encephalopathy such as seizures, or other cen-
trally localizing neurological signs of acute onset. Furthermore, cats
were excluded, if azotemia was related to acute kidney injury or
decompensated CKD or to known pre- or post-renal factors or to con-
siderable risk for the cat not to complete the entire study period. Fur-
thermore, cats with confirmed or suspected concomitant diseases
such as diabetes mellitus, congestive heart failure, or neoplasia were
ineligible.
2.2 | Study design
This multicenter prospective, randomized, double-blinded, placebo-
controlled study with parallel group design was conducted according
to Good Clinical Practice principles.25
The study consisted of a 28 day efficacy phase and a subsequent
92-day extended use phase.
Physical examination, fundoscopy, and SABP measurement were
performed before inclusion and on study days 14, 28, 56, 84, and 120.
Blood samples were collected in ethylenediaminetetraacetic acid and
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serum tubes and sent to Vet Med Labor GmbH (Germany) before the
start of study and on study days 28 and 120. Urine was collected by
cystocentesis and analyzed by the same laboratory before inclusion.
During the efficacy phase, cats were randomly assigned at a rate
of 2 : 1 to telmisartan oral solution at a dosage of 2 mg/kg or an opti-
cal identical oral placebo once daily. This treatment dose was chosen
based on the results of a previous study.26 The randomization was
performed using a covariate-adaptive randomization procedure with
the focus on achieving an approximate ratio of 2 : 1 for telmisartan
and placebo with respect to the 2 stratifying factors “classification of
hypertension” and “study site,” while also including a random compo-
nent.27 In every randomization step, the current imbalance from the
expected 2 : 1 ratio was determined for each of the stratifying factors.
This allocation scheme ensured an approximate treatment ratio of
2 : 1 for each site separately and for each HT class across sites.27
Dose reduction in 0.5 mg/kg increments to a minimum dose of
0.5 mg/kg was only allowed if signs of hypotension were observed in
combination with an SABP <100 mmHg. Dose reduction was under-
taken even in the absence of clinical signs of hypotension if SABP
<80 mmHg. An increase of the dose was not permitted in the study
protocol.
After Day 28, treatment was unmasked and cats treated with tel-
misartan were allowed to enter the extended use phase. During this
phase, the telmisartan dose could be decreased at the discretion of
the investigator if the cat's SABP was <160 mmHg. The target SABP
range was defined as 120-160 mmHg. Cats with SABP >200 mmHg
were removed from the study and treated at the discretion of the
attending clinician.
Routine treatments with no known impact on systemic HT (eg,
vaccinations, antiparasitic drugs) were allowed during the study. Anti-
inflammatory drug treatment during the study was only permitted as
short-term (<14 days) treatment. The protocol was prepared in con-
sultation with independent experts and approved by local authorities,
when required. All adverse events (AEs) were reported in accordance
with local regulations.
2.3 | Statistical methods
A composite primary efficacy end point was defined a priori for the
evaluation of telmisartan efficacy. The first co-primary end point was
the difference in mean SABP change from baseline to Day 14 between
the telmisartan and placebo treatment group, which was tested by a
2-sided 2-sample Student's t test with alpha = 0.05 (SAS software,
Version 9.4; SAS Institute, Cary, North Carolina). The null hypothesis
of no difference in mean SABP change between telmisartan and pla-
cebo after 14 days treatment was tested for the per protocol set
(PPS) population. The second co-primary end point was clinically rele-
vant mean SABP reduction for telmisartan, defined by a mean SABP
decrease >20 mmHg between baseline SABP and SABP on study day
28. The ACVIM consensus statement defined the goal of systemic HT
treatment of cats as achieving a reduction in the category of risk for
future TOD.4 The primary end point criterion that the mean SABP
reduction should be ≥20 mmHg fulfilled this goal completely, because
it assured that the risk of the included cat group for future TOD is
reduced by at least 1 category on Day 28 compared to baseline after
the ACVIM HT consensus statement.
For animals excluded from the study on study day 14 or thereaf-
ter due to SABP >200 mmHg or development of acute or severe
TOD, missing SABP data were imputed on the subsequent visits using
the last observation carried forward (LOCF) method, imputing the last
observed SABP from the same animal.
A sample size calculation was performed by simulations using the
SAS software (version 9.3, SAS Institute) and calculated as the number
of animals required to successfully achieve both co-primary end
points. The original assumptions of the sample size calculation were
reviewed within an a priori planned interim analysis. In the latter, only
the required number of animals was provided to prevent any potential
unblinding. This sample size calculation indicated that 294 cats were
required to evaluate the efficacy of telmisartan over placebo (ratio tel-
misartan/placebo 2 : 1) with alpha = 0.05, a power of 80%, 10% drop-
outs without LOCF data available, and using the following
assumptions for effect and variability estimates: mean telmisartan
SABP change = −24 mmHg (SD = 23.7 mmHg), mean placebo SABP
change = −16 mmHg (SD = 20.6 mmHg).
Additional analyses were performed by scheduled study visits and
treatment using descriptive statistics: subgroup analysis on mean SABP
reduction, frequency of animals with SABP according to IRIS TOD cate-
gorization or >15% decrease compared to baseline SABP, frequency of
animals with SABP reduction of >20 mmHg, mean SABP reduction
according to SABP at baseline, and change in telmisartan dose. The 1st
co-primary end point was assessed also for SABP reduction from base-
line at Day 28. Uncertainty of the treatment effects was measured using
95% confidence intervals (CIs). The proportions of cats with minimal risk
of TOD and the proportions of cats with SABP reduction >20 mmHg
were compared for Day 28 between groups using chi-square tests. The
proportions of telmisartan-treated cats with minimal risk of TOD was
compared between Days 14 and 28 using chi-square test.
The efficacy of study treatments was assessed on the basis of the
PPS population. This group comprised all study animals having reached
at least study day 14. Cases of relevant deviations from the protocol (eg,
enrollment of cat although exclusion criterion was fulfilled) and cases not
subjected to all the relevant assessments (eg, study protocol was not fol-
lowed due to owner’s noncompliance) were not included in the PPS. The
intention to treat (ITT) population included cats that had at least 1 docu-
mented dose of telmisartan or placebo administered, at least 1 analyzable
data parameter available, and major entry criteria were satisfied. The
safety (SAF) population included all cats that had received at least 1 dose
of telmisartan or placebo. The SAF population was used for the analysis
of AEs, which were reported by the participating veterinarians and for
the analysis of clinicopathologic data. Incidence of AEs was summarized
descriptively by treatment groups and the proportions of cats that expe-
rienced at least 1 AE were compared between groups by a chi-
square test.
3 | RESULTS
Out of 818 documented screened cats, a total of 294 cats were
enrolled, on average 6 cats per site, and included in the SAF data set
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(Figure 1). Of those, 285 formed the ITT population and 262 cats
comprised the PPS. The end of the placebo controlled study phase
(Day 28) was reached by 165 telmisartan-treated cats and 87 pla-
cebo-treated cats. One placebo- and 2 telmisartan-treated cats were
removed from the study before Day 28 due to SABP >200 mmHg
according to the study protocol. For the efficacy analysis, however,
their data were included using the LOCF method. By the end of an
additional 2nd phase (Day 120) additional 21 cats had discontinued
the study, due to lost to follow-up (4 cats), AEs (3 cats: renal failure in
1 cat; hypersalivation in 1 cat; anorexia, diarrhea, vomiting, and renal
failure in 1 cat), or withdrawal of owner consent (9 cats). Six cats were
removed due to SABP >200 mmHg in this 2nd phase of the study.
Age, body weight, breed distribution, causes of systemic HT, and
baseline SABP were similar in both groups (Table 1). Males and
females were not evenly distributed in both groups with more males
in the placebo group. However, the mean reduction of SABP after
28 days was comparable between the neutered males and females in
both treatment groups.
The primary analysis showed a significant difference in mean
SABP change between the telmisartan and placebo groups on Day
14 (P < .001) and a clinically relevant mean telmisartan SABP reduc-
tion of 24.6 mmHg on Day 28; hence, both co-primary end points
Assessed for eligibility (n = 818) 
Screening failure* (n = 524): 
• SABP less than 160 (n=197), 
• Total T4 greater than 60 (n=63), 
• No signature of Owner Consent (n=33), 
• Cat has concomitant disease (n=12), 
• SABP greater than 200 (n=7) 
• Cat has azotemia due to renal disease (n=6), 
• Cat has TOD (n=6), 
• Severe TOD (n=3), 
• Withdrawal of consent (n=3), 
• Euthanized (n=2), 
• Other (n=183), Unknown (n=9) 
* Screening examinations were discontinued upon 
identification of a reason not to include the cat 
SAF Population: 
Allocated to Telmisartan (n=194) 
SAF Population: 
Allocated to placebo (n=100) 
Allocation 
ITT Population (n=96): 
Removal from SAF due to: 
• No analyzable data parameter is available after 
randomization (n=3), 
• Major entry criterion was not met (n=1) 
PPS Population (n=174): 
Removal from ITT due to: 
• No D14 visit (n=4), 
• Inclusion criteria not met (n=1), 
• Exclusion criteria was met (n=5), 
• Treatment non compliance (n=5) 
PPS Population (n=88): 
Removal from ITT due to: 
• Exclusion criteria was met (n=2), 
• Treatment non compliance (n=6) 
ITT Population (n=189): 
Removal from SAF due to: 
• No study drug administration documented (n=1), 
• No analyzable data parameter is available after 
randomization (n=3), 
• Major entry criterion was not met (n=1) 
Reason for cat removal from PPS 
population in efficacy phase: 
• Owner non compliance (n=3) 
• Difficulty with study drug administration (n=3) 
• Euthanasia due to lack of eating and drinking 
(n=1) 
• Adverse event (hemorrhagic gastroenteritis, 
dyspnoea) (n=2) 
Reason for cat removal from PPS 
population in efficacy phase: 
• Owner non compliance (n=1) 
FIGURE 1 Participant flow
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were successfully achieved (Table 2, Figure 2). In order to check the
primary analysis result for robustness, the testing procedure was
reperformed for the ITT population as well. Both co-primary end
points were achieved in the ITT population with similar results
(Table 2). The mean SABP reduction from baseline in the PPS popula-
tion was 19.2 (95% CI: 15.92-22.52) mmHg for the telmisartan group
and 9.0 (95% CI: 5.30-12.80) mmHg for the placebo group on Day
14, and 24.6 (95% CI: 21.11-28.14) mmHg for the telmisartan group
and 11.4 (95% CI: 7.94-14.95) mmHg for the placebo group on Day
28. The difference in mean SABP change between the telmisartan and
placebo groups was statistically significant on Day 28 (P < .001) as
well. The mean reduction in SABP was not dependent on the concur-
rent disease or the presence of idiopathic HT, neither in the telmisar-
tan nor in the placebo group. The proportion of cats with SABP
reduction >20 mmHg on Day 28 was significantly different between
groups (telmisartan: 55% [90/165 cats], placebo: 28% [24/87 cats],
P < .001). By Day 28, the proportion of cats with a SABP <150 mmHg
or >15% decrease compared to baseline SABP was significantly differ-
ent between the groups (telmisartan: 52% [85/165 cats], placebo:
25% [22/87 cats], P < .001). Between Days 14 and 28, the proportion
TABLE 1 Baseline characteristics of the telmisartan and placebo groups (ITT and PPS population)
Variable
Telmisartan Placebo
ITT (n = 189) PPS (n = 174) ITT (n = 96) PPS (n = 88)
Baseline SABP (mmHg): Mean (SD) 179.3 (9.9) 179.1 (10.0) 177.4 (9.9) 177.3 (10.1)
Demographics
Female: % (n) 50.8 (96) 48.9 (85) 37.5 (36) 38.6 (34)
Male: % (n) 49.2 (93) 51.1 (89) 62.5 (60) 61.4 (54)
Intact: % (n) 4.2 (8) 4.0 (7) 0.0 (0) 0.0 (0)
Neutered/spayed: % (n) 95.8 (181) 96.0 (167) 100.0 (96) 100.0 (88)
Age (years): Mean (SD) 13.3 (3.4) 13.3 (3.4) 13.1 (3.5) 13.2 (3.5)
Body weight (kg): Mean (SD) 4.4 (1.2) 4.4 (1.2) 4.5 (1.3) 4.5 (1.4)
Breeda
British %: (n) 3.7 (7) 3.4 (6) 3.1 (3) 3.4 (3)
Crossbreed %: (n) 4.8 (9) 5.2 (9) 2.1 (2) 2.3 (2)
Domestic short/long hair: % (n) 76.7 (145) 75.9 (132) 80.2 (77) 79.5 (70)
Persian %: (n) 4.8 (9) 5.2 (9) 7.3 (7) 8.0 (7)
Cause of hypertension
CKD: % (n) 30.2 (57) 29.9 (52) 31.3 (30) 30.7 (27)
Hyperthyroidism: % (n) 7.4 (14) 7.5 (13) 7.3 (7) 8.0 (7)
CKD + hyperthyroidism: % (n) 4.8 (9) 4.6 (8) 5.2 (5) 5.7 (5)
Idiopathic: % (n) 57.7 (109) 58.0 (101) 56.3 (54) 55.7 (49)
Abbreviations: CKD, chronic kidney disease; ITT, intention to treat; PPS, per protocol set; SABP, systolic arterial blood pressure.
aBreeds with frequency below 3% are not shown.
TABLE 2 Mean change in SABP (mmHg) in the telmisartan and placebo groups (PPS and ITT)
Mean change of SABP (mmHg) Telmisartan Placebo Primary analysis
PPS population
On Day 14a −19.2 −9.0 Comparison of mean
95% CI −22.52 to −15.92 −12.80 to −5.30 SABP reduction between
Number of cats (n) n = 174 n = 88 groups: P < .001
On Day 28a −24.6 −11.4 Clinical relevance
95% CI −28.14 to −21.11 −14.95 to −7.94 defined as mean SABP
Number of cats (n) n = 165 n = 87 reduction >20 mmHg
ITT population
On Day 14b −19.2 −8.8 Comparison of mean
95% CI −22.4 to −16.0 −12.4 to −5.3 SABP reduction between
Number of cats (n) n = 185 n = 96 groups: P < .001
On Day 28b −24.5 −10.8 Clinical relevance
95% CI −27.9 to −21.0 −14.4 to −7.1 defined as mean SABP
Number of cats (n) n = 174 n = 94 reduction >20 mmHg
Abbreviations: CI, confidence interval; ITT, intention to treat; PPS, per protocol set; SABP, systolic arterial blood pressure.
aBaseline SABP (mmHg) mean (SD): telmisartan: 179.1 (9.9), placebo: 177.3 (10.1).
bBaseline SABP (mmHg) mean (SD): telmisartan: 179.3 (9.9), placebo: 177.4 (9.9).
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of telmisartan-treated cats with an SABP <150 mmHg or >15%
decrease compared to baseline SABP significantly increased (Day 14:
34% [60/174], Day 28: 52% [85/165]; P < .001).
In the 2nd phase of the study, the mean decrease in SABP from
baseline in the telmisartan group was persistent over time on Days
56, 84, and 120 (Tables 3 and 4).
The mean reduction in SABP in the telmisartan group in the
severely hypertensive category (≥180 mmHg) was comparable to
those with moderate systemic HT (160-179 mmHg) (Table 5).
The starting telmisartan dose of 2 mg/kg PO q24 was administered
to all cats in the efficacy phase of the study. The majority of cats were
continued on this dose (112/143 cats; 78%), whereas some cats (31/143
cats; 22%) were down titrated to a dose of 1.5 mg/kg or lower.
No clinically relevant changes in routine hematological and bio-
chemical parameters at study end compared to baseline were
observed (Table 6).
The proportion of cats with at least 1 AE during the efficacy
phase was similar in both groups (telmisartan: 30% [58/194 cats], pla-
cebo: 29% [29/100 cats], P = .89). Overall, the incidence of cats with
at least 1 AE was low in the efficacy phase (Table 7). The frequency of
cats with at least 1 AE was comparable or lower in the extended use
phase compared to the above-mentioned frequencies in the efficacy
phase. Hypotension was observed at 1% (2/194 cats) of the
telmisartan-treated cats in the efficacy phase and also at 1% (2/194
cats) of the cats in the extended use phase. No hypotension was
observed in the placebo group.
4 | DISCUSSION
In this large clinical field study, it was demonstrated that telmisartan
lowers the mean SABP in cats with systemic HT compared to placebo,
controls SABP over time and is well tolerated.
In the cats of this study, representing patients as seen by veteri-
narians in daily practice, mean reduction of SABP was significantly dif-
ferent between the telmisartan and placebo groups on Day 14 and
the mean reduction in response to telmisartan was deemed clinically
relevant as the mean SABP decreased by more than 20 mmHg in the
telmisartan group by Day 28. The effect on lowering mean SABP and
the proportion of cats with SABP <150 mmHg to minimize TOD4,28
increased between Days 14 and 28 without an increase of the dose,
and the antihypertensive effect was persistent over the 120-day
FIGURE 2 Mean (95% confidence interval of the mean) changes from baseline in systolic arterial blood pressure during the blinded efficacy
phase (per protocol set population)
TABLE 3 Mean SABP reduction compared to baseline and frequency of cats with SABP <150 mmHg or a ≥15% SABP decrease from baseline in
the telmisartan group; frequency of cats with SABP change >20 mmHg compared to baseline in telmisartan and placebo groups (PPS population)
Visit
Change of SABP from
baseline (mmHg) mean (SD) (n)
Percentage of cats with
SABP < 150 mmHg or
an SABP decrease from
baseline ≥15% (n)
Percentage of cats with
SABP change >20 mmHg
compared to baseline
in the telmisartan group
Percentage of cats with
SABP change >20 mmHg
compared to baseline in
the placebo group
Day 14 −19.2 (22.1) (n = 174) 34.5 (60) 42.5 (74) 27.3 (24)
Day 28 −24.6 (22.9) (n = 165) 51.5 (85) 54.5 (90) 27.6 (24)
Day 56 −26.9 (24.0) (n = 152) 56.5 (86) 63.2 (96) NA
Day 84 −26.5 (25.2) (n = 148) 57.4 (85) 61.5 (91) NA
Day 120 −27.6 (26.9) (n = 144) 60.4 (87) 66.7 (96) NA
Abbreviations: NA, not applicable; PPS, per protocol set; SABP, systolic arterial blood pressure.
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study duration. This observation was reconfirmed by the results
obtained after repeating the analysis without those cats that dropped
out during the study with a high blood pressure. This finding is similar
to those in human patients, in which it is known that after the first
dose of telmisartan, the antihypertensive activity gradually becomes
evident within 3 hours, and the maximum reduction in blood pressure
is generally attained 4-8 weeks after the start of treatment and is sus-
tained during long-term treatment.21 The observed mean SABP reduc-
tion in the telmisartan group was in line with the assumption based on
the interim analysis. The assumption regarding the mean SABP change
in the placebo group based on the interim analysis was somewhat
higher compared to the result of the study. This discrepancy in pla-
cebo effect estimates might be related to the lower number of avail-
able cats in the placebo group at the time the interim analysis was
performed due to the 2 : 1 randomization ratio.
Although, the role of the RAAS in systemic HT of cats is not fully
understood, the results of the present study suggest that activation of
the RAAS might be involved in the pathogenesis, as systemic HT could
be successfully controlled, independent of the underlying disease or
idiopathic HT. The relative lack of efficacy of ACE inhibitors (ACEis) in
treating systemic HT in cats observed by others8,15,16,29 could be
explained by the use of an inadequate dosage, inadequate conversion
of angiotensinogen into AT1 receptor agonists without the involve-
ment of conventional ACE. An alternative explanation might be the
fact that ARBs leave the AT2 receptor effects of AT-II intact.
The mean SABP decrease in placebo-treated cats of around
10 mmHg on Day 14, which persisted until Day 28, had been also
observed in a previous study.18 This might be due to a training effect
regarding the procedure of measuring blood pressure, respectively the
fading of a white coat effect over time.30 Another potential hypothe-
sis, although less likely, might be a true placebo effect, resulting from
either how the veterinarian approached the blood pressure measure-
ment process or how the owners treated the cat. Whatever the rea-
son, this finding illustrates the importance of including a placebo
group for blood pressure trials in veterinary medicine.
Telmisartan at a starting dose of 2 mg/kg PO q24h was well toler-
ated and safe to use in this study of cats with HT, as was found previ-
ously when telmisartan was used at half this dose in a group of elderly
cats with CKD.23 Generally medications targeting the RAAS, such as
ACEis, or ARBs might induce a decline in glomerular filtration rate par-
ticularly in cases with late stage kidney disease or in dehydrated ani-
mals with CKD and regular monitoring according to good clinical
practice is deemed appropriate. However, there was no increase in
mean serum creatinine in cats treated with telmisartan in this study,
even in the subgroup of cats with IRIS stage 2 and 3 CKD.
There are some differences between the present study and the
previous randomized controlled clinical trial involving the use of amlo-
dipine in hypertensive cats that are worthwhile mentioning. One is
that SABP in the present study was measured by Doppler compared
to high-definition oscillometry in a previous study.18 The Doppler
TABLE 4 Frequency of cats in SAPB categories according to IRIS TOD categorization (PPS population)
Telmisartan Placebo
Sample
size
Percentage of cats with SABP in the following range (n)
Sample
size
Percentage of cats with SABP in the following range (n)
<150 mmHga
≥150 mmHg
and
<160 mmHg
≥160 mmHg
and
<180 mmHg ≥180 mmHg <150 mmHga
≥150 mmHg
and
<160 mmHg
≥160 mmHg
and
<180 mmHg ≥180 mmHg
Day 14 174 34.5 (60) 12.6 (22) 32.8 (57) 20.1 (35) 88 25 (22) 5.7 (5) 31.8 (28) 37.5 (33)
Day 28 165 51.5 (85) 10.3 (17) 23.0 (38) 15.2 (25) 87 25.3 (22) 14.9 (13) 31 (27) 28.7 (25)
Day 56 152 56.6 (86) 14.5 (22) 13.8 (21) 15.1 (23) NA NA NA NA NA
Day 84 148 57.4 (85) 8.8 (13) 18.9 (28) 14.9 (22) NA NA NA NA NA
Day 120 144 60.4 (87) 8.3 (12) 15.3 (22) 16 (23) NA NA NA NA NA
Abbreviations: IRIS, International Renal Interest Society; NA, not applicable; PPS, per protocol set; SABP, systolic arterial blood pressure; TOD, target organ
damage.
aor SABP decrease from baseline ≥15%.
TABLE 5 Mean SABP reduction over time compared to baseline in the telmisartan and placebo groups in cats with SABP at baseline between
160 and 179 mmHg and 180 and 200 mmHg (PPS population)
SABP at baseline
Between 160 and 179 mmHg Between 180 and 200 mmHg
Telmisartan baseline SABP
mean: 171.9 mmHg (n = 98)
Placebo baseline SABP
mean: 170.9 mmHg (n = 56)
Telmisartan baseline SABP
mean: 188.4 mmHg (n = 76)
Placebo baseline SABP
mean: 188.5 mmHg (n = 32)
Visit Mean SABP reduction compared to baseline at respective visit (mmHg)
Day 14 16.7 (n = 98) 8.8 (n = 56) 22.3 (n = 76) 9.5 (n = 32)
Day 28 22.9 (n = 94) 11.9 (n = 55) 26.6 (n = 71) 10.9 (n = 32)
Day 56 24.7 (n = 87) NA 29.6 (n = 65) NA
Day 84 23.2 (n = 85) NA 30.7 (n = 63) NA
Day 120 23.5 (n = 81) NA 32.9 (n = 63) NA
Abbreviations: NA, not applicable; PPS, per protocol set; SABP, systolic arterial blood pressure.
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methodology was chosen as at the start of the study it was the most
commonly used method by practitioners and none of the available
methods had been fully validated according to the ACVIM consensus
statement criteria. Another difference in the studies was the criteria
to define a responder. In the present study, the mean SABP reduction
in the telmisartan group had to be both, significantly different com-
pared to placebo at Day 14 and to be higher than 20 mmHg compared
to baseline at Day 28. The criteria in a previous study were decrease
of SABP to <150 mmHg or decrease from baseline of at least 15%.18
In the previous study, the dosage of amlodipine was doubled at Day
14 in 54% of the cats due to nonresponse at the starting dose, which
was not allowed in the present study; higher doses of telmisartan
could have increased the number of responders in the present study.
Another difference is that cats receiving ACEi were ineligible for inclu-
sion in the present study, whereas in a previous study 15.6% of the
enrolled cats were on concomitant ACEi treatment.18
Common causes of systemic HT in the present study were CKD,
hyperthyroidism, and a combination of the 2. This was not unex-
pected, because these are the most common reported causes of sys-
temic HT in cats, and therefore such cats are specifically screened.4
However, the percentage of cats with idiopathic HT seemed to be rel-
atively high in comparison to previous publications reporting
17%-23% of the investigated cats having idiopathic HT.5,31,32 One
explanation for this finding might be the definitions of CKD and
hyperthyroidism. In the present study, CKD was diagnosed if the cat
had urine specific gravity below 1.035 combined with plasma creati-
nine above 1.6 mg/dL or abnormal kidneys on palpation or on ultra-
sound or on radiographic examination. Euthyroidism was defined as
serum total T4 < 60 μmol/L; however, hyperthyroidism might already
be present at a T4 > 40 μmol/L.7 Another reason might be whitecoat
HT contributing to the placebo effect, which might be present in an
unknown number of cats enrolled in this study. Furthermore, there
are relatively few studies in the literature documenting the prevalence
of HT in cats, and most publications are biased toward screening only
those populations of cats that are deemed to be at risk. In the present
study, by contrast, not only cats at risk of HT because of the underly-
ing concomitant diseases were screened but a more general cat popu-
lation. Although, there might have been differences among the
selection of screened cats at each study center, the high number of
participating study sites resulted in a overall group of screened cats,
which reflected a more general cat population. Thus, it is entirely pos-
sible that more idiopathic hypertensive cats were recruited to the pre-
sent study because cats registered with primary care practitioners
were screened more widely for HT than in previous studies. Even if
the percentage of idiopathic HT is overestimated in this study, it nev-
ertheless supports previous reports in which idiopathic HT was a com-
mon finding in cats.3,31,32 Overall, regular screening of adult cats for
systemic HT, particularly aiming to prevent TOD as recommended in
recent systemic HT guidelines28 is supported by this study as
reflected in the high number of cats with increased blood pressure in
the screened group.
The observed AEs were attributed to concurrent medical condi-
tions and not associated with telmisartan administration. Due to the
mode of action of telmisartan, transient hypotension might occur,
although it was observed at a very low rate throughout the study.
Symptomatic treatment, for example, fluid treatment, should be pro-
vided in case of any clinical signs of hypotension.
A limitation of the present study was the exclusion of cats with
SABP above 200 mmHg (ie, cats with most severe systemic HT and
highest risk of TOD) as it was considered unethical to enroll such cats
where the risk of TOD appears to be extremely high into a placebo-
controlled study. In accordance, the primary end point criterion that
the mean SABP reduction should be ≥20 mmHg would not necessarily
lead to a reduction in the category of risk for future TOD if cats with
SABP above 200 mmHg would have been included. Nevertheless, it is
expected that telmisartan would efficiently lower SABP also in these
cats based on the observation in the present study as SABP was as
effectively controlled as in cats with less severe systemic HT. In a
recent published case report of a severely hypertensive cat, telmisar-
tan as monotherapy effectively controlled blood pressure, whereas
benazepril as monotherapy was unsuccessful after amlodipine had to
be withdrawn due to development of gingival hyperplasia.33 Further
limitations such as excluding cats with severe CKD from the study,
the relatively high number of cats classified as idiopathic HT or
TABLE 6 Laboratory variables of telmisartan- and placebo-treated cats at baseline, on Days 28 and 120 (SAF population)
Variable (SD)
Telmisartan (n=194a) Placebo (n=100a)
Reference rangeBaseline Day 28 Day 120 Baseline Day 28
Erythrocytes (T/L): Mean (SD) 8.58 (1.48) 8.21 (1.58) 8.28 (1.67) 8.41 (1.57) 8.52 (1.52) 5-10 T/L
PCV (%) mean (SD) 40.1 (6.1) 37.9 (6.3) 38.7 (6.3) 38.7 (7.2) 38.9 (6.2) 28%-45%
Creatinine (mg/dL) mean (SD) 1.74 (0.81) 1.73 (0.75) 1.72 (0.68) 1.66 (0.72) 1.63 (0.66) <1.9 mg/dL
BUN (mmol/L) mean (SD) 12.96 (5.68) 12.92 (4.69) 13.12 (5.13) 12.44 (5.57) 12.89 (6.01) 5.7-13.5 mmoL/L
Potassium (mmol/L) mean (SD) 4.50 (0.55) 4.53 (0.58) 4.47 (0.54) 4.54 (0.49) 4.51 (0.49) 3.3-5.8 mmoL/L
Abbreviations: BUN, blood urea nitrogen; SAF, safety.
aSample size of listed variables might be lower.
TABLE 7 Overview of adverse events with incidence ≥2% during the
efficacy phase (safety population)
Adverse event
Percentage of cats (number of cats)
Telmisartan
(n = 194)
Placebo
(n = 100)
Overall
(n = 294)
All adverse events 29.9 (58) 29.0 (29) 29.6 (87)
Emesis 6.2 (12) 6.0 (6) 6.1 (18)
Hypertension 2.6 (5) 4.0 (4) 3.1 (9)
Anorexia 3.6 (7) 1.0 (1) 2.7 (8)
Diarrhea 2.1 (4) 3.0 (3) 2.4 (7)
Tachycardia 3.1 (6) 1.0 (1) 2.4 (7)
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whitecoat HT contributing to the placebo effect, have been discussed
in more detail above.
Future studies are warranted to determine the optimal dose
required to meet the target posttreatment blood pressure in cats with
pretreatment blood pressure in excess of 200 mmHg.
In summary, telmisartan oral solution at 2 mg/kg q24h proved to
lower SABP by a clinically relevant magnitude and duration in the
absence of significant treatment-related AEs. Thus, telmisartan is a
valuable option for the treatment of systemic HT in cats.
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